{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=temozolomide+150+mg%2Fm%5E2&page=2", "query": { "intervention": "temozolomide 150 mg/m^2", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 51, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=temozolomide+150+mg%2Fm%5E2&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=temozolomide+150+mg%2Fm%5E2&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T16:41:41.389Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00734526", "title": "Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Gliosarcoma" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2008-12-18", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2018-11-09", "last_synced_at": "2026-10-06T16:41:41.389Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00734526" }, { "nct_id": "NCT00508456", "title": "Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "Temodar (Temozolomide)", "type": "DRUG" }, { "name": "Hominex-2", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 18, "start_date": "2004-08", "completion_date": "2008-11", "has_results": false, "last_update_posted_date": "2012-01-16", "last_synced_at": "2026-10-06T16:41:41.389Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00508456" }, { "nct_id": "NCT02340156", "title": "Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "RECURRENT GLIOBLASTOMA" ], "interventions": [ { "name": "SGT-53", "type": "GENETIC" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "DRUG" ], "sponsor": "SynerGene Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2014-12", "completion_date": "2018-11", "has_results": true, "last_update_posted_date": "2021-03-03", "last_synced_at": "2026-10-06T16:41:41.389Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02340156" }, { "nct_id": "NCT06428045", "title": "STARLITE for Unresectable High-Grade Gliomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "High Grade Glioma" ], "interventions": [ { "name": "Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT)", "type": "PROCEDURE" }, { "name": "Abacavir", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Focal Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2025-04-15", "completion_date": "2030-04-30", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-06T16:41:41.389Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06428045" }, { "nct_id": "NCT03426891", "title": "Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Brain Tumor", "GBM" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2018-03-16", "completion_date": "2023-06-28", "has_results": true, "last_update_posted_date": "2025-10-06", "last_synced_at": "2026-10-06T16:41:41.389Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03426891" }, { "nct_id": "NCT00112502", "title": "Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Glioblastoma Multiforme" ], "interventions": [ { "name": "Celecoxib", "type": "DRUG" }, { "name": "Isotretinoin", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 178, "start_date": "2005-09", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2021-10-18", "last_synced_at": "2026-10-06T16:41:41.389Z", "location_count": 12, "location_summary": "Fort Smith, Arkansas • Orlando, Florida • Atlanta, Georgia + 9 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Wichita", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00112502" }, { "nct_id": "NCT04421378", "title": "A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Temozolomide (TMZ)", "type": "DRUG" }, { "name": "Lomustine (CCNU)", "type": "DRUG" }, { "name": "Standard Fractionated Radiation therapy (RT)", "type": "RADIATION" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "TTField", "type": "DEVICE" }, { "name": "Carmustine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "DEVICE" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2020-06-08", "completion_date": "2023-07-03", "has_results": true, "last_update_posted_date": "2024-12-16", "last_synced_at": "2026-10-06T16:41:41.389Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04421378" }, { "nct_id": "NCT01506609", "title": "Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Veliparib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 294, "start_date": "2012-01-23", "completion_date": "2020-09-02", "has_results": true, "last_update_posted_date": "2021-10-25", "last_synced_at": "2026-10-06T16:41:41.389Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01506609" }, { "nct_id": "NCT02344355", "title": "A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "Ascorbic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Bryan Allen", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2017-03-13", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-06T16:41:41.389Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT02344355" }, { "nct_id": "NCT00544817", "title": "Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2007-04", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2016-09-01", "last_synced_at": "2026-10-06T16:41:41.389Z", "location_count": 10, "location_summary": "Fort Myers, Florida • Gainesville, Georgia • Bethesda, Maryland + 7 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Gainesville", "state": "Georgia" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00544817" } ] }